VICTORIA, BRITISH COLUMBIA--(Marketwire - April 13, 2011) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") today announced that it has issued 500,000 common shares to Equity Communications Ontario, Ltd. ("Equity Communications") at a price of $0.06 per share. The shares were issued at the request of Equity Communications under a strategic advisory agreement between the parties. The shares issued are subject to a four month hold period expiring August 13, 2011.
Etienne Grima, CEO of the Company, said, "This is another example of the show of corporate support for CardioComm Solutions' planned business expansion into the global mobile medical monitoring marketplace, and its continuous development of innovative EKG technologies."
Ira Weingarten, founder and President of Equity Communications, commented, "CardioComm Solutions is addressing the demand for much needed products and medical monitoring services that can be delivered across a broad range of wireless platforms. As a next generation medical provider, CardioComm Solutions' world-class software infrastructure will prove to offer a trusted platform compatible with iOS and Android technologies enabling the delivery of new medical monitoring applications around the world in compliance with FDA and CE requirements."
About CardioComm Solutions, Inc.
CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm's software enables real-time viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global mobile healthcare network. This technology is marketed as Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.
On behalf of the Board of Directors of CardioComm Solutions, Inc.
Etienne Grima, CEO
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.